Clinical Trials
17 trialsNCT07548710 2026-06-03
Study of SA+X in the Treatment of Newly Diagnosed AML
Ruijin Hospital
Phase 2 Recruiting
NCT04250051 2026-06-01
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
Phase 1 Terminated
NCT07607418 2026-05-26
Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
Ruijin Hospital
Phase 2 Recruiting
NCT04493164 2026-05-22
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04774393 2026-05-20
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05401097 2026-05-13
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06707493 2026-04-28
Ivosidenib as Post-HSCT Maintenance for AML
Massachusetts General Hospital
Phase 2 Recruiting
NCT05756777 2026-03-27
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT03471260 2026-03-11
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07463768 2026-03-11
MIVONU
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
NCT07392242 2026-03-06
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05010772 2026-01-14
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07131059 2025-08-20
MRD-positive AML Clinical Study
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT03503409 2025-05-18
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies
Phase 2 Active not recruiting
NCT03839771 2024-10-02
HOVON150AML
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Active not recruiting
NCT04655391 2022-06-09
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
City of Hope Medical Center
Phase 1 Withdrawn
NCT04044209 2022-01-20
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Yale University
Phase 2 Withdrawn